Lumateperone or Placebo for Depressive Episodes in Bipolarity
About this title
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
Read the official source — NCT03249376Researchers compared Lumateperone and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.
Understand this study
What did researchers investigate?
Researchers compared Lumateperone and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 46 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 381
- Sponsor
- Intra-Cellular Therapies, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Colombia, ...
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT03249376
- Official title
Show the full official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) Conducted Globally
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Birmingham, United States · Sherman Oaks, United States · Miami, United States
45 more locations
- Orange City, United States
- Atlanta, United States
- Decatur, United States
- Chicago, United States
- Joliet, United States
- Shreveport, United States
- St Louis, United States
- Buffalo, United States
- Charlotte, United States
- The Woodlands, United States
- Bothell, United States
- Burgas, Bulgaria
- Kardzhali, Bulgaria
- Lovech, Bulgaria
- Plovdiv, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Tsarev Brod, Bulgaria
- Varna, Bulgaria
- Veliko Tarnovo, Bulgaria
- Barranquilla, Colombia
- Bello, Colombia
- Pereira, Colombia
- Moscow, Russia
- Nizhny Novgorod, Russia
- Omsk, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Saratov, Russia
- Tomsk, Russia
- Yekaterinburg, Russia
- Belgrade, Serbia
- Kragujevac, Serbia
- Novi Sad, Serbia
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Smila, Ukraine
- Uzhhorod, Ukraine
- Vinnytsia, Ukraine
- Russia
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Lumateperone and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.
Who is behind this study?
The study sponsor is Intra-Cellular Therapies, Inc.
Did this study involve medication?
Yes. The study involved medication, including Lumateperone.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
